Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
Changjun Wang, Ying Xu, Yan Lin, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 21

Showing 21 citing articles:

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, et al.
The Oncologist (2023) Vol. 28, Iss. 10, pp. 845-855
Open Access | Times Cited: 23
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Banu K. Arun, Fergus J. Couch, Jean Abraham, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 10
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Melinda L. Telli, Jennifer K. Litton, J. Thaddeus Beck, et al.
Breast Cancer (2024) Vol. 31, Iss. 5, pp. 886-897
Open Access | Times Cited: 6
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
Loïck Galland, Nicolas Roussot, Isabelle Desmoulins, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1299-1299
Open Access | Times Cited: 14
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
Loïck Galland, Elise Ballot, Hugo Mananet, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 19
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
Vilma Pacheco-Barcía, Andrés J. Muñoz Martín, Elena Castro, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2950-2950
Open Access | Times Cited: 19
Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis
Corrado Tinterri, Simone Di Maria Grimaldi, Andrea Sagona, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4177-4177
Open Access | Times Cited: 11
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
Neslihan Cabıoğlu, Semen Önder, Gizem Öner, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 19
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Zheng Wang, Yujie Lu, Mengyuan Han, et al.
Breast Cancer Research and Treatment (2024) Vol. 208, Iss. 2, pp. 429-440
Open Access | Times Cited: 2
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
Emma Zattarin, Ida Taglialatela, Riccardo Lobefaro, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 190, pp. 104109-104109
Closed Access | Times Cited: 6
Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
Olga Caramelo, Cristina Silva, Francisco Caramelo, et al.
Hereditary Cancer in Clinical Practice (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 10
Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis
Changjun Wang, Yan Lin, Hanjiang Zhu, et al.
Breast Cancer (2021) Vol. 29, Iss. 2, pp. 314-323
Closed Access | Times Cited: 13
Pathological complete response following cisplatin or carboplatin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: A systematic review and meta‑analysis
Radu Vidra, Adina Nemeș, Andreea Vidrean, et al.
Experimental and Therapeutic Medicine (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis
Changjun Wang, Yan Lin, Hanjiang Zhu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
Wanyi Sun, Yun Wu, Fei Ma, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1588-1588
Open Access | Times Cited: 4
Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
Jianyun Yin, Changtai Zhu, Gaofeng Wang, et al.
International Journal of General Medicine (2022) Vol. Volume 15, pp. 5901-5914
Open Access | Times Cited: 7
Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis
Ying Jiang, Xiangyu Meng, Ning-Ning Deng, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
Qin He, Yicheng Peng, Jie Sun, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients
Naveed Syed, Ashish V. Chintakuntlawar, Deepti Vilasini, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 7, pp. 848-858
Open Access
Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
М. М. Цыганов, Sofia S. Sorokovikova, Elizaveta Andreevna Lutzkaya, et al.
Genes (2023) Vol. 14, Iss. 8, pp. 1554-1554
Open Access | Times Cited: 1
Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis
Yingxuan Zhu, Yang Li, Weida Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access
Page 1

Scroll to top